References
Boivin G P, Molina J R, Ormsby I, Stemmermann G and Doetschman T 1996 Gastric lesions in transforming growth factor beta-1 heterozygous mice;Lab. Invest. 74 513–518
Ee Y S, Lai L C, Reimann K and Lim P K 1999 Effect of transforming growth factor-beta 1 on oestrogen metabolism in MCF-7 and MDA-MB-231 breast cancer cell lines;Oncol. Rep. 6 843–846
Engle S J, Hoying J B, Boivin G P, Ormsby I, Gartside P S and Doetschman T 1999 Transforming growth factor beta 1 suppresses nonmetastatic colon cancer at an early stage of tumourigenesis;Cancer Res. 59 3379–3386
Erbas H and Lai L C 2000 Effect of transforming growth factor beta 2 on oestrogen metabolism in the MCF-7 breast cancer cell line;J. Clin. Pathol. 53 322–324
Erbas H, Lennard T W and Lai L C 1999 Latent forms of transforming growth factor-beta 2 (TGF-beta 2) in breast cyst fluid;Anticancer Res. 19 3077–3082
Joseph H, Gorska A E, Sohn P, Moses H L and Serra R 1999 Over expression of a kinase-deficient transforming growth factor-beta type II receptor in mouse mammary stroma results in increased epithelial branching;Mol. Biol. Cell 10 1221–1234
Massague J 1998 TGF-beta signal transduction;Annu. Rev. Biochem. 67 753–791
Nguyen A V and Pollard J W 2000 Transforming growth factor beta 3 induces cell death during the first stage of mammary gland involution;Development 127 3107–3118
O’Connor-McCourt M D and Wakefield L M 1987 Latent transforming growth factor-beta in serum. A specific complex with alpha 2-macroglobulin;J. Biol. Chem. 262 14090–14099
Pelton R W, Saxena B, Jones M, Moses H L and Gold L I 1991 Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in the mouse embryo: expression patterns suggest multiple roles during embryonic development;J. Cell Biol. 115 1091–1105
Proetzel G, Pawlowski S A, Wiles M V, Yin M, Boivin G P, Howles P N, Ding J, Ferguson M W and Doetschman T 1995 Transforming growth factor-beta 3 is required for secondary palate fusion;Nature Genet. 11 409–414
Roberts A B and Sporn M B 1990 The transforming growth factorbetas; inPeptide growth factors and their receptors — Handbook of experimental pathology (eds) M B Sporn and A B Roberts (Heidelberg: Springer-Verlag) pp 419–472
Robinson S D, Silberstein G B, Roberts A B, Flanders K C and Daniel C W 1991 Regulated expression and growth inhibitory effects of transforming growth factor-beta isoforms in mouse mammary gland development;Development 113 867–878
Sanford L P, Ormsby I, Gittenberger-de Groot A C, Sariola H, Friedman R, Boivin G P, Cardell E L and Doetschman T 1997 TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes;Development 124 2659–2670
Shull M M, Ormsby I, Kier A B, Pawlowski S, Diebold R J, Yin M, Allen R, Sidman C, Proetzel G, Calvin D and Doetschman T 1992 Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease;Nature (London) 359 693–699
Torres R M and Kühn R 1997Laboratory protocols for conditional gene targeting (New York: Oxford University Press) pp 11–13
Wakefield L M, Letterio J J, Chen T, Danielpour D, Allison R S, Pai L H, Denicoff A M, Noone M H, Cowan K H and O’Shaughnessy J A 1995 Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer;Clin. Cancer. Res. 1 129–136
Walker R A 2000 Transforming growth factor beta and its receptors: their role in breast cancer;Histopathology 36 178–180
Zhu Y, Richardson J A, Parada L F and Graff J M 1998 Smad3 mutant mice develop Metastatic colorectal cancer;Cell 94 703–714
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Azhar, M. Non-redundant tumour suppressor functions of transforming growth factor beta in breast cancer. J Biosci 26, 9–12 (2001). https://doi.org/10.1007/BF02708975
Issue Date:
DOI: https://doi.org/10.1007/BF02708975